Table 3 Fold change of genes in LNCaP cells exposed to combination treatment or mono-treatment with Taxotere or Furtulon
Gene | Taxotere | Furtulon | Taxotere+Furtulon | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Â | 6 h | 36 h | 72 h | 6 h | 36 h | 72 h | 6 h | 36 h | 72 h |
Cell cycle and apoptosis | Â | Â | Â | Â | Â | Â | Â | Â | Â |
NM_001786.1 cell division cycle 2 (CDC2) | -1.2 | -7.5 | -12.1 | -1.1 | -2.8 | -1.6 | NC | -4.0 | -14.9 |
D88357.1 mRNA for CDC2 delta T | -1.1 | -6.1 | -14.9 | NC | -2.8 | -1.6 | -1.1 | -4.3 | -13.0 |
NM_001237.1 cyclin A2 (CCNA2) | -1.2 | -5.7 | -12.1 | NC | NC | -2.1 | -1.1 | -8.6 | -13.9 |
NM_004702.1 cyclin E2 (CCNE2) | 1.6 | -5.3 | -3.2 | NC | -2.3 | -1.7 | -1.7 | -4.9 | -8.0 |
AF112857.1 cyclin E2 splice variant 1 mRNA | 1.2 | -3.5 | -3.2 | NC | -2.0 | -1.6 | -1.4 | -7.0 | -8.6 |
NM_001761.1 cyclin F (CCNF) | -1.5 | -2.5 | -3.7 | -1.1 | -1.1 | -2.0 | -1.4 | -2.3 | -2.8 |
AB012305.1 cyclin-dependent kinase 2 | -1.7 | -3.5 | -5.3 | -2.0 | -2.1 | -2.1 | NC | -2.8 | -3.5 |
U30872.1 mitosin mRNA | -1.2 | -4.6 | -6.1 | NC | -2.1 | -1.3 | NC | -3.2 | -7.0 |
NM_000389.1 cyclin-dependent kinase inhibitor 1A (p21, Cip1) | 1.3 | 9.8 | 8.6 | 1.0 | 2.0 | 2.0 | 1.0 | 8.0 | 7.5 |
NM_006763.1 BTG family, member 2 (BTG2) | 1.5 | 6.1 | 6.5 | 1.1 | 1.7 | 2.1 | 1.4 | 5.3 | 3.7 |
NM_006472.1 upregulated by 1,25-dihydroxyvitamin D-3 (VDUP1) | 1.0 | 3.5 | 3.5 | 1.0 | 1.5 | 2.6 | 1.0 | 2.3 | 3.0 |
NM_001924.2 growth arrest and DNA-damage-inducible, alpha | 1.4 | 7.5 | 7.5 | NC | 1.9 | 2.6 | 1.1 | 7.0 | 7.5 |
BC003637.1 Similar to DNA-damage-inducible transcript 3 | 1.0 | 2.6 | 2.6 | 1.1 | 2.1 | 2.5 | NC | 2.6 | 2.8 |
NM_014454.1 p53 regulated PA26 nuclear protein (PA26) | 1.1 | 4.0 | 3.0 | 1.1 | 1.4 | 2.6 | 1.1 | 3.7 | 3.7 |
NM_004701.2 cyclin B2 (CCNB2) | -1.1 | -8 | -13.9 | NC | 1.3 | -1.3 | -1 | -4.9 | -19.7 |
NM_001255.1 CDC20 (cell division cycle 20) | -1.9 | -90.5 | -147 | NC | 1.6 | -1.9 | -1.6 | -13 | -157 |
NM_021873.1 cell division cycle 25B (CDC25B) | -1.1 | -1.6 | -2.5 | NC | NC | -1.4 | -1 | -2.3 | -3.25 |
NM_001827.1 CDC28 protein kinase 2 (CKS2) | -1.1 | -4.6 | -6.5 | NC | 1.6 | -1.6 | -1.2 | -3.5 | -5.7 |
NM_001168.1 survivin (BIRC5) | -1.1 | -27.9 | -294 | NC | NC | -1.6 | NC | -6.9 | -181 |
Transcription, translation, oncogenesis, angiogenesis, other | Â | Â | Â | Â | Â | Â | Â | Â | Â |
NM_021953.1 forkhead box M1 (FOXM1) | -1.2 | -13.9 | -42.2 | -1.1 | -1.2 | -2.0 | NC | -2.8 | -45.3 |
NM_000465.1 BRCA1 associated RING domain 1 (BARD1) | -1.3 | -1.9 | -2.0 | NC | -1.1 | -2.1 | -1.2 | -2.6 | -4.9 |
NM_003368.1 ubiquitin specific protease 1 (USP1) | NC | -2.6 | -1.6 | NC | -2.0 | -1.4 | NC | -2.1 | -1.9 |
NM_006716.1 activator of S phase kinase (ASK) | -1.2 | -6.5 | -5.3 | -1.2 | -1.3 | -2.0 | -1.1 | -4.6 | -11.3 |
NM_003246.1 thrombospondin 1 (THBS1) | NC | -2.0 | -3.5 | -1.9 | -1.4 | -2.6 | -1.1 | -1.6 | -4.6 |
NM_001147.1 angiopoietin 2 (ANGPT2) | 3.5 | 3.5 | 8.0 | 1.7 | 5.3 | 8.0 | -0.5 | 4.9 | 2.8 |
AF187858.1 angiopoietin-2 isoform-1 | NC | 2.6 | 4.3 | NC | 1.5 | 3.5 | NC | 2.0 | 2.0 |
NM_000435.1 Notch (Drosophila) homolog 3 (NOTCH3) | 1.3 | 3.0 | 2.8 | 1.0 | 2.3 | 2.1 | NC | 2.1 | 3.0 |
NM_001674.1 activating transcription factor 3 (ATF3) | NC | 1.5 | 2.5 | NC | 1.7 | 2.5 | NC | 2.6 | 4.3 |
NM_003158.1 serinethreonine kinase 6 (STK6) | -1.7 | -11.3 | -9.8 | 1.1 | 1.2 | -1.7 | -1.3 | -8.6 | -26 |
NM_003600.1 serinethreonine kinase 15 (STK15) | -1.2 | -3.7 | -8.6 | NC | NC | -1.6 | -1.3 | -4 | -6.1 |
AF162704.1 androgen receptor mRNA | NC | 1.3 | -1.6 | 1.2 | 1.3 | -2.1 | -1.1 | -1.6 | -2 |
Resistance to chemotherapeutic agents | Â | Â | Â | Â | Â | Â | Â | Â | Â |
NM_000693.1 aldehyde dehydrogenase 1A3 (ALDH1A3) | NC | 4.0 | 3.2 | 1.0 | 1.1 | 2.1 | 1.2 | 4.9 | 4.3 |
NM_005980.1 S100 calcium-binding protein P (S100P) | 1.0 | 5.7 | 4.0 | 1.5 | 2.6 | 3.0 | NC | 2.6 | 2.6 |